tirzepatide surgery Tirzepatide Hartford What to Expect Before and

ECC5004 is a once daily, low dose, small molecule GLP-1RA which is currently in a US Phase I clinical trial in healthy participants and patients with type 2 diabetes

How does tirzepatide compare

When Eli Lilly published Phase 2 trial data in 2023, participants lost an average of 24.2% of body weight at the highest dose over 48 weeks

Sahebkar, A., Serban, M

People who begin obesity treatment with glucagon-like peptide-1 receptor agonists (GLP-1s) and then undergo metabolic and bariatric surgery achieve substantially greater weight loss than with the medications alone, according to new research presented today at the annual meeting of the American Society for Metabolic and Bariatric Surgery (#ASMBS2026)

Its always important to remember that when a company promotes content about the treatments it sells, it isnt education